SCYNEXIS, Inc. (SCYX) NASDAQ
4.69
-0.195(-4.00%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
4.69
-0.195(-4.00%)
Currency In USD
| Previous Close | 4.88 |
| Open | 4.99 |
| Day High | 4.99 |
| Day Low | 4.64 |
| 52-Week High | 10.48 |
| 52-Week Low | 4.52 |
| Volume | 44,994.99 |
| Average Volume | 74,680 |
| Market Cap | 29.46M |
| PE | -1.22 |
| EPS | -3.84 |
| Moving Average 50 Days | 7.03 |
| Moving Average 200 Days | 6.36 |
| Change | -0.2 |
SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247
GlobeNewswire Inc.
Feb 26, 2026 1:23 PM GMT
Results from IV Phase 1 SAD/MAD Trial Expected in 2026JERSEY CITY, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-re
SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
GlobeNewswire Inc.
Jan 28, 2026 1:00 PM GMT
This cross-disciplinary meeting highlights the latest discoveries, technologies and translational strategies driving the next generation of antimicrobial solutionsJERSEY CITY, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a
SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247
GlobeNewswire Inc.
Jan 21, 2026 1:00 PM GMT
The QIDP designation will ensure at least 10 years of market exclusivity for SCY-247 following approval Recent articles highlight the growing threat from a rapidly spreading, multi-drug resistant, Candida auris fungal infection JERSEY CITY, N.J., Ja